Aarti Drugs FY26 PAT Up 16% YoY to ₹194.9 Cr

Aarti Drugs Ltd announced its audited financial results for Q4 and FY26. The company's revenue for FY26 stood at ₹2,567.7 crore, a 7% YoY increase. EBITDA was ₹311.6 crore, up 3% YoY, with a margin of 12.1%. PAT reached ₹194.9 crore, a 16% YoY increase, with a margin of 7.6%. Q4 FY26 revenue was ₹721.1 crore, up 6% YoY, while PAT was ₹55.3 crore, down 12% YoY. The Sayakha facility achieved a run-rate of ~1,000 tonnes per month in March 2026.